Kezar Life Sciences Inc
KZR6.340USD
+0.020+0.32%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
46.43MMarket Cap
0.09P/E TTM
More Details of Kezar Life Sciences Inc Company
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). The Company is focused on the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage. Its PORTOLA is a placebo-controlled, double-blind Phase IIa clinical trial of zetomipzomib in patients with AIH that were insufficiently responding to standard of care or have relapsed.
Kezar Life Sciences Inc Info
Ticker SymbolKZR
Company nameKezar Life Sciences Inc
IPO dateJun 21, 2018
CEOKirk (Christopher)
Number of employees55
Security typeOrdinary Share
Fiscal year-endJun 21
Address4000 Shoreline Ct Ste 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080-2005
Phone16508225600
Websitehttps://kezarlifesciences.com/
Ticker SymbolKZR
IPO dateJun 21, 2018
CEOKirk (Christopher)
Company Executives of Kezar Life Sciences Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Franklin Fowler
Mr. John Franklin Fowler
Director
Director
43.61K
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Independent Director
Independent Director
6.37K
--
Mr. Marc L. Belsky
Mr. Marc L. Belsky
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
1.87K
-0.05%
Dr. Christopher Kirk, Ph.D.
Dr. Christopher Kirk, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Micki Klearman, M.D.
Dr. Micki Klearman, M.D.
Independent Director
Independent Director
--
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Courtney Wallace
Ms. Courtney Wallace
Independent Director
Independent Director
--
--
Mr. Mark Schiller
Mr. Mark Schiller
Chief Legal Officer
Chief Legal Officer
--
--
Dr. Elizabeth Garner, M.D.
Dr. Elizabeth Garner, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Franklin Fowler
Mr. John Franklin Fowler
Director
Director
43.61K
--
Dr. Michael G. Kauffman, M.D., Ph.D.
Dr. Michael G. Kauffman, M.D., Ph.D.
Independent Director
Independent Director
6.37K
--
Mr. Marc L. Belsky
Mr. Marc L. Belsky
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
1.87K
-0.05%
Dr. Christopher Kirk, Ph.D.
Dr. Christopher Kirk, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Micki Klearman, M.D.
Dr. Micki Klearman, M.D.
Independent Director
Independent Director
--
--
Mr. Franklin M. Berger
Mr. Franklin M. Berger
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BML Capital Management LLC
9.84%
Tang Capital Management, LLC
9.83%
Suvretta Capital Management, LLC
9.79%
Equal Talent Investments, Ltd.
8.42%
Stonepine Capital Management, LLC
5.23%
Other
56.89%
Shareholders
Shareholders
Proportion
BML Capital Management LLC
9.84%
Tang Capital Management, LLC
9.83%
Suvretta Capital Management, LLC
9.79%
Equal Talent Investments, Ltd.
8.42%
Stonepine Capital Management, LLC
5.23%
Other
56.89%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.19%
Investment Advisor
18.43%
Investment Advisor/Hedge Fund
9.07%
Corporation
8.42%
Private Equity
2.63%
Individual Investor
2.15%
Research Firm
0.14%
Other
31.98%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
173
4.68M
63.85%
-1.14M
2025Q2
206
5.15M
70.47%
-1.71M
2025Q1
258
5.21M
71.33%
-2.10M
2024Q4
278
5.09M
69.66%
-2.04M
2024Q3
292
4.99M
68.49%
-2.51M
2024Q2
303
5.03M
68.99%
-2.99M
2024Q1
309
5.63M
77.32%
-2.93M
2023Q4
309
6.08M
83.70%
-2.64M
2023Q3
309
6.63M
91.19%
-2.23M
2023Q2
309
7.09M
97.92%
-2.02M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BML Capital Management LLC
635.18K
8.67%
+227.04K
+55.63%
Jun 30, 2025
Tang Capital Management, LLC
720.00K
9.83%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
716.76K
9.79%
--
--
Jun 30, 2025
Equal Talent Investments, Ltd.
616.50K
8.42%
--
--
Feb 28, 2025
Stonepine Capital Management, LLC
377.24K
5.15%
+207.38K
+122.09%
Sep 02, 2025
The Vanguard Group, Inc.
276.23K
3.77%
--
--
Jun 30, 2025
OrbiMed Advisors, LLC
192.70K
2.63%
--
--
Jun 30, 2025
Acadian Asset Management LLC
133.53K
1.82%
--
--
Jun 30, 2025
Peapod Lane Capital LLC
115.12K
1.57%
-9.30K
-7.48%
Jun 30, 2025
Adar1 Capital Management LLC
147.40K
2.01%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
Global X Russell 2000 Covered Call ETF
0%
ProShares UltraPro Russell2000
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 3000 ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Global X Russell 2000 Covered Call ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 28, 2024
Merger
10→1
Oct 28, 2024
Merger
10→1
Oct 28, 2024
Merger
10→1
Oct 28, 2024
Merger
10→1
Date
Type
Ratio
Oct 28, 2024
Merger
10→1
Oct 28, 2024
Merger
10→1
Oct 28, 2024
Merger
10→1
Oct 28, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Kezar Life Sciences Inc?
The top five shareholders of Kezar Life Sciences Inc are:
BML Capital Management LLC holds 635.18K shares, accounting for 8.67% of the total shares.
Tang Capital Management, LLC holds 720.00K shares, accounting for 9.83% of the total shares.
Suvretta Capital Management, LLC holds 716.76K shares, accounting for 9.79% of the total shares.
Equal Talent Investments, Ltd. holds 616.50K shares, accounting for 8.42% of the total shares.
Stonepine Capital Management, LLC holds 377.24K shares, accounting for 5.15% of the total shares.
BML Capital Management LLC holds 635.18K shares, accounting for 8.67% of the total shares.
Tang Capital Management, LLC holds 720.00K shares, accounting for 9.83% of the total shares.
Suvretta Capital Management, LLC holds 716.76K shares, accounting for 9.79% of the total shares.
Equal Talent Investments, Ltd. holds 616.50K shares, accounting for 8.42% of the total shares.
Stonepine Capital Management, LLC holds 377.24K shares, accounting for 5.15% of the total shares.
What are the top three shareholder types of Kezar Life Sciences Inc?
The top three shareholder types of Kezar Life Sciences Inc are:
BML Capital Management LLC
Tang Capital Management, LLC
Suvretta Capital Management, LLC
BML Capital Management LLC
Tang Capital Management, LLC
Suvretta Capital Management, LLC
How many institutions hold shares of Kezar Life Sciences Inc (KZR)?
As of 2025Q3, 173 institutions hold shares of Kezar Life Sciences Inc, with a combined market value of approximately 4.68M, accounting for 63.85% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -6.62%.
What is the biggest source of revenue for Kezar Life Sciences Inc?
In --, the -- business generated the highest revenue for Kezar Life Sciences Inc, amounting to -- and accounting for --% of total revenue.
